In vitro assessment finds gepotidacin effective against ceftriaxone-resistant Neisseria gonorrhoeae, indicating potential for treatment.
Overall, gepotidacin was active in vitro against this challenging panel of ceftriaxone-resistant gonococcal clinical isolates. Gepotidacin activity does not seem to be affected in this ceftriaxone-resistant set of strains. A structural analysis suggests that the rare GyrA A92P alteration identified in this study does not affect gepotidacin binding.
No takes yet. Share an insight, caveat, or question.
Cole et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: